Cartesian Therapeutics (RNAC) Non-Current Assets (2015 - 2026)

Cartesian Therapeutics (RNAC) has 12 years of Non-Current Assets data on file, last reported at $166.4 million in Q1 2026.

• Quarterly Non-Current Assets fell 25.74% year-over-year to $166.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $784.4 million (down 12.02% YoY) and the FY2025 annual result came in at $167.1 million, down 23.47% from the prior year.
• Non-Current Assets held at $166.4 million in Q1 2026 per RNAC's latest filing, from $167.1 million in the prior quarter.
• Across five years, Non-Current Assets topped out at $226.2 million in Q3 2024 and bottomed at $15.5 million in Q2 2022.
• The 5-year median for Non-Current Assets is $167.1 million (2025), against an average of $130.7 million.
• The widest annual swing landed in 2024, when Non-Current Assets soared 1299.2%; it then fell 25.74% in 2026.
• Tracing RNAC's Non-Current Assets over 5 years: stood at $17.7 million in 2022, then soared by 1107.58% to $214.3 million in 2023, then grew by 1.9% to $218.4 million in 2024, then fell by 23.47% to $167.1 million in 2025, then dropped by 0.47% to $166.4 million in 2026.
• Per Business Quant, the three latest RNAC Non-Current Assets figures stand at $166.4 million (Q1 2026), $167.1 million (Q4 2025), and $225.4 million (Q3 2025).

Peer Comparison